<?xml version="1.0" encoding="UTF-8"?>
<p>All the 
 <italic>in vitro</italic> and 
 <italic>in vivo</italic> biological properties shown by these classes of compounds highlight a very interesting potential for the treatment of AD. Even if there is still the need of improving selectivity and lowering cytotoxicity, these hybrid structures are once again proving how different pharmacophoric elements, joined by an appropriate and specifically designed linker, represent a valuable starting point that deserves to be progressed as MTDL drugs.
</p>
